media – Page 11 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Federal Pharmaceuticals subsidiary obtains approval for new antibiotic product

On July 17, United Laboratories (03933) announced that the injection of amoxicillin sodium and clavulanate potassium (specifications: 0.6g, 1.2g) applied by the company’s wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd. Zhongshan Branch, has been approved by the China National Drug Administration and successfully passed the generic drug quality and efficacy consistency evaluation. This product is a broad-spectrum penicillin antibiotic with the characteristics of significantly enhanced antibacterial activity and is suitable for the treatment of a variety of infections. This approval will further consolidate the company’s dominant position in the anti-infection field. The company said it will continue to focus on new product development and promote consistency evaluation, which is expected to create greater benefits for the company and its shareholders. https://finance.eastmoney.com/a/202507183460816649.html
- Source: drugdu
- 48
- July 22, 2025
Yuanda Pharmaceutical’s world’s first nasal spray product for the treatment of dry eyes enters clinical application

According to the announcement made by Yuanda Pharmaceutical on the evening of July 17, the company’s first nasal spray product for increasing tear secretion in patients with dry eye syndrome, Varenicline Tartrate Nasal Spray (OC-01), has been officially approved and implemented the first batch of commercial prescriptions in mainland China at the First Affiliated Hospital of Sun Yat-sen University and Shenzhen Eye Hospital. This marks that the only nasal spray product currently approved for increasing tear secretion in patients with dry eye syndrome in China has officially entered clinical application. It is disclosed that dry eye is a common chronic ocular surface disease in clinical practice. The incidence of dry eye in China is about 21%-30%, and the number of dry eye patients is conservatively estimated to be about 360 million. At present, dry eye patients visiting outpatient clinics in medical institutions account for more than 30% of the total ...
- Source: drugdu
- 53
- July 22, 2025
The Central Plains Zhengzhou Medical Device Exhibition (CWMEE)

Organiser: CWMEE Organizing Committee Time：September 11-13, 2025 address：No.1 Central Park, Business Inner Ring Road, Zhengdong New District, Zhengzhou City, Henan Province Exhibition hall：Zhengzhou International Convention and Exhibition Center Product range: Medical Devices: Various new medical instruments and medical supporting instruments, cardiac monitors, medical imaging equipment, biochemical analyzers, blood pressure monitors, thermometers, and other types of home medical equipment. Testing Equipment and Supplies: Blood analysis systems, biochemical analysis systems, immunoanalysis systems, bacterial analysis systems, urine analysis systems, clinical laboratory testing auxiliary equipment, diagnostic reagents, blood testing reagents, etc. Diagnostic Equipment: Ultrasound diagnostic equipment, X-ray imaging diagnostic equipment, electrocardiogram and encephalogram monitoring equipment, scanning equipment, biochemical testing equipment, rehabilitation and physiotherapy equipment, functional examination equipment, pathological diagnostic equipment, endoscopic examination equipment, optical instruments, and examination and diagnostic equipment for neurology, orthopedics, otolaryngology, ophthalmology, etc. Therapeutic Equipment: Surgical equipment for internal and external medicine, radiotherapy equipment, nuclear medicine treatment equipment, laser equipment, physiotherapy ...
- Source: drugdu
- 86
- July 22, 2025
Corneal contact caps of a subsidiary of GSV Medical have been approved by the Guangdong Food and Drug Administration

On July 17, Gaush Medical (02407) issued an announcement that the “corneal contact cap” of its subsidiary ShenzhenGaush Technology Co., Ltd. has been approved by the Guangdong Provincial Food and Drug Administration for medical devices.Registration certificate (Registration certificate number: Guangdong Medical Device Registration No. 20252161020). This product is used to cover the corneal microscope objective lens of the confocal ophthalmic laser diagnostic equipment when the patient’s cornea is tomographically scanned, which can effectively avoid cross infection and ensure the safety of the diagnosis and treatment process. The corneal contact cap consists of two parts: the corneal contact plane and the cone cover. It is made of high-quality medical-grade optical plastic and is formed by precision injection molding. The product has a flat and smooth surface, no scratches or impurities, and excellent light transmission performance, which can minimize light loss and refraction interference. In addition, the structural design of the product fits ...
- Source: drugdu
- 68
- July 21, 2025
Xinhua Medical obtains two medical device registration certificates

July 17, Xinhua Medical(600587) announced that the company has recently obtained two medical device certificates issued by the Shandong Provincial Drug Administration.The registration certificates are for anesthesia machines, ventilator circuit disinfectors and electric beds. The registration certificate number of the anesthesia machine ventilator circuit disinfection machine is Lu Xie Zhu Zhun 20252110405, the approval date is July 4, 2025, and it is valid until July 3, 2030. The registration certificate number of the electric bed is Lu Xie Zhu Zhun 20252150409, the approval date is July 7, 2025, and it is valid until July 6, 2030. The launch of these two products will enrich the company’s product line. The anesthesia machine ventilator circuit disinfection machine provides a convenient and safe disinfection method for medical units, while the electric bed meets the different body position requirements of patients during treatment and improves nursing efficiency. The announcement pointed out that the launch ...
- Source: drugdu
- 52
- July 21, 2025
Tiantan Biopharma launches Phase III clinical trial for new indication of intravenous human immunoglobulin

On the evening of July 17, Tiantan BiotechnologyDisclose announcements on the progress of clinical trials of drugs of affiliated companies. The announcement shows that the company’s subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd.’s marketed product “Intravenous Human Immunoglobulin (pH4)” (10%, 50ml) has completed clinical ethics review, pre-clinical preparations and other work for the new indication of chronic inflammatory demyelinating polyradiculoneuropathy, and has officially started Phase III clinical trials recently. This newly added indication is the first intravenous human immunoglobulin product in China to be approved for clinical research on the indication of chronic inflammatory demyelinating polyradiculoneuropathy. The main procedures that need to be fulfilled for the above-mentioned product to be approved for the new indication include: completing Phase III clinical trials, submitting an application for a license for the new indication, and obtaining approval for the new indication after passing the review of the Drug Evaluation Center of the National Medical ...
- Source: drugdu
- 53
- July 21, 2025
Huluwa was approved by the Food and Drug Administration for the consistency evaluation of Ceftriaxone Sodium for Injection

July 17, ST Huluwa(605199) issued an announcement that it recently received the “Notice of Approval of Drug Supplementary Application” for Ceftriaxone Sodium for Injection approved and issued by the National Drug Administration. The drug has successfully passed the generic drug quality and efficacy consistency evaluation. The specifications of the drug are 1.0g and 2.0g, the manufacturer is the company, and the original drug approval number is National Medicine Standard H20043257. The approval conclusion of this time confirms that this product meets the consistency evaluation standards according to the provisions of relevant laws and regulations, and agrees to change the drug quality standards and packaging materials that directly contact the drug.and container. As of the date of disclosure of the announcement, in addition to the company, more than three manufacturers have passed the consistency evaluation of the drug. The company has invested a total of RMB 3.61 million in research and ...
- Source: drugdu
- 51
- July 21, 2025
First-to-First GLP-1 Launches New Clinical Trial of “Head-to-Head” Semaglutide

Sciwind Biopharma has registered a new clinical trial on the Drug Clinical Trial Registration and Information Disclosure Platform: a multicenter, randomized, open-label, switch treatment phase II study (SLIMMER-UP-SWITCH) on the efficacy and safety of XW003 injection versus semaglutide injection in obese patients. If the Phase II results are positive, it will further verify the clinical advantages of its world-first cAMP-biased GLP-1 mechanism and accelerate its impact on the 100 billion weight loss market. https://bydrug.pharmcube.com/news/detail/63af1637f55a1e3fc18e6a3e70bc5dd6
- Source: drugdu
- 50
- July 21, 2025
Baili Tianheng’s dual-antibody ADC combination therapy for advanced renal cancer has been approved for Phase II clinical trial

Baili Tianheng announced that it recently received the “Notice of Approval for Drug Clinical Trial” officially approved and issued by the National Medical Products Administration (NMPA). The company’s independently developed innovative biological drug Iza-bren (EGFR×HER3 dual-antibody ADC) combination drug Phase II clinical trial was approved for use in a clinical trial combined with lenvatinib ± pembrolizumab to treat advanced renal cancer. This therapy combines lenvatinib and pembrolizumab, which is expected to enhance the anti-tumor effect through multi-target synergy and fill the unmet needs in the field of renal cancer treatment. If the clinical trial goes smoothly, it will enhance the company’s competitiveness in the ADC track. https://m.cnstock.com/commonDetail/469101
- Source: drugdu
- 48
- July 21, 2025
BeiGene/Amgen’s DLL3/CD3 bispecific antibody is approved for domestic market launch

The CDE official website shows that BeiGene and Amgen’s application for taratumumab injection has been accepted for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have failed at least 2 lines of treatment (including platinum-containing chemotherapy). This indication has been included in the priority review. Globally, only one DLL3/CD3 dual antibody, taratumumab, has been approved for marketing. In addition, there are 4 other products that have entered the clinical stage, with the highest progress being clinical phase II. In terms of clinical progress, taratumumab has a first-mover advantage. https://finance.sina.com.cn/roll/2025-07-17/doc-infftyiu0311325.shtml
- Source: drugdu
- 47
- July 21, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.